Improved Conformational ControlHigher Target AffinityEnhanced Proteolytic StabilityOptimized Developability
We provide integrated cyclic peptide design services to support hit discovery, lead optimization, and preclinical candidate selection for peptide therapeutics. Our platform combines sequence design, cyclization strategy selection, structure-activity relationship analysis, permeability and stability optimization, and manufacturability assessment to generate cyclic peptide leads with stronger binding, improved metabolic resilience, and more attractive developability profiles. Whether your program targets difficult protein-protein interactions, oncology receptors, antimicrobial mechanisms, or intracellular pathways, we tailor each workflow to your target biology, screening strategy, and downstream CMC requirements.
Cyclic peptide design is the process of engineering peptide sequences in which the backbone or side chains are covalently constrained to form a ring or multicyclic architecture. Compared with linear peptides, cyclic formats often provide lower conformational entropy upon binding, improved resistance to proteases, and better selectivity against challenging targets. In practice, design decisions are driven by target class, preferred binding epitope, route of administration, and developability requirements such as solubility, permeability, serum stability, and synthetic accessibility. Our teams integrate rational sequence design, AI-driven cyclic peptide design, and medicinal chemistry optimization to move from exploratory concepts to data-supported leads suitable for follow-up synthesis and biological testing.
3D molecular model of a cyclic peptide scaffold used for structure-guided affinity, stability, and developability optimization.
Translating cyclic peptides into viable drug candidates requires more than ring closure. We help clients solve the scientific and development issues that most often limit progression:
Effective cyclic peptide design balances target biology with molecular properties. The most successful programs do not optimize potency in isolation; they align binding mode, topology, polarity, and synthetic feasibility from the beginning so that hits remain developable as they mature into lead candidates.
| Design Parameter | Why It Matters | Typical Optimization Levers | When It Becomes Critical |
|---|---|---|---|
| Conformational Constraint | Improves target recognition and can reduce entropic loss on binding | Ring closure position, ring size, stapling, bicyclization | PPI targets, shallow binding surfaces, selectivity-driven projects |
| Proteolytic Stability | Supports systemic exposure and cleaner PK interpretation | Cyclization, D-residues, N-methylation, non-natural amino acids | In vivo efficacy studies, plasma-rich environments, repeat dosing |
| Permeability | Determines suitability for intracellular or tissue-penetrant targets | Hydrogen-bond masking, lipophilicity tuning, backbone editing | Intracellular targets, oral delivery exploration, CNS-oriented programs |
| Solubility | Affects assay reliability, formulation options, and doseability | Charge balance, polar substitutions, salt form, excipient strategy | High-concentration studies, parenteral development, screening cascades |
| Target Selectivity | Reduces off-target pharmacology and supports cleaner biology packages | Hotspot-focused substitutions, topology refinement, counterscreen-informed analogs | Receptor families, homologous enzymes, safety-sensitive programs |
| Synthetic Accessibility | Limits project delay from low cyclization yield or purification burden | Sequence simplification, orthogonal protection, route redesign | Scale-up planning, analog-rich SAR campaigns, fast iteration timelines |
| Analytical Traceability | Ensures confidence in identity, purity, and structure-property interpretation | LC-MS mapping, peptide mapping, NMR, impurity profiling | Candidate nomination, tech transfer, GLP-supportive studies |
Cyclization chemistry strongly influences affinity, stability, permeability, and manufacturability. We select the closure strategy according to sequence context, desired rigidity, and the degree of chemical complexity the program can support in later development.
| Cyclization Strategy | Structural Effect | Development Advantages | Best-Fit Use Cases |
|---|---|---|---|
| Head-to-Tail Macrocyclization | Constrains the full peptide backbone into a compact ring | Often delivers strong protease resistance and clear conformational control | Natural-product-inspired scaffolds, receptor ligands, broad SAR campaigns |
| Side-Chain-to-Side-Chain Lactam | Creates a localized constraint without fully closing the backbone | Useful for preserving active conformations while retaining design flexibility | Helical motifs, epitope-focused designs, potency rescue studies |
| Disulfide Cyclization | Introduces reversible conformational locking through cysteine pairing | Fast exploratory option for screening and topology scouting | Early hit finding, extracellular targets, biologically reducing environments not dominant |
| Thioether or Stable Side-Chain Linkage | Produces chemically robust macrocycles with limited reversibility | Higher chemical stability than disulfides and good translational potential | Systemic therapeutics, serum-exposed programs, candidate-quality scaffolds |
| Stapled / Hydrocarbon-Constrained Peptides | Reinforces secondary structure, especially helical presentation | Can improve helicity, protease resistance, and cellular uptake | Intracellular PPIs, transcription-factor interfaces, helical binding motifs |
| Bicyclic and Multicyclic Formats | Deliver highly rigid architectures with multiple constrained loops | Excellent for affinity maturation and difficult selectivity problems | Challenging targets, enzyme inhibitors, high-stringency lead programs |
Choosing a cyclic format should be justified by target and development data rather than trend alone. The table below summarizes why macrocyclization is often valuable in therapeutic peptide design, while also highlighting where linear formats may still be preferable.
| Property | Cyclic Peptides | Linear Peptides | Development Implication |
|---|---|---|---|
| Conformational Flexibility | Lower; binding conformation can be partially preorganized | Higher; often more adaptable but less controlled | Cyclic formats are attractive when affinity and selectivity depend on shape definition |
| Protease Resistance | Commonly improved, especially with additional backbone engineering | Frequently more susceptible to rapid degradation | Cyclic peptides are often preferred for systemic exposure or longer assay windows |
| Permeability Potential | Can be improved through polarity management and conformational shielding | Often limited unless short or highly modified | Cyclic peptides can address intracellular targets when property optimization is deliberate |
| Synthetic Simplicity | More complex because ring closure efficiency must be controlled | Usually simpler for early synthesis and quick analog generation | Early screening may begin linear, but promising motifs often benefit from later cyclization |
| SAR Readout | Rich but topology dependent; ring editing can change multiple properties at once | Often easier to interpret residue-by-residue in the first pass | Project design should include both sequence SAR and topology SAR when using macrocycles |
| Best-Fit Applications | PPI inhibitors, oncology ligands, antimicrobial scaffolds, long-lived binders | Rapid epitope mapping, simple receptor ligands, exploratory screening tools | Format selection should match target complexity and intended development path |
Target-to-Candidate Perspective
We design cyclic peptides with discovery, developability, and CMC implications in view rather than optimizing potency in isolation.
Medicinal Chemistry Depth
Our design logic incorporates SAR, ring topology, non-natural residues, and property tuning relevant to real peptide drug programs.
Broad Cyclization Toolkit
We support monocyclic, bicyclic, disulfide, lactam, thioether, and stapled formats to match different target classes and development risks.
Design Linked to Synthesis Reality
Sequence proposals are reviewed for manufacturability, purification burden, and likely impurity behavior before large analog sets are commissioned.
Data-Driven Optimization
We combine modeling, biophysical interpretation, and assay feedback to refine affinity, stability, and permeability with clear decision criteria.
Discovery-to-Preclinical Continuity
Clients can move from hit design into synthesis, analytical characterization, and scale-up planning without restarting with a new vendor.
Clear Technical Reporting
We structure projects around milestone-based recommendations, analog prioritization, and interpretable SAR summaries for internal portfolio decisions.
Strong Confidentiality Practices
Sensitive target information, sequence space, and proprietary screening data are handled under project-specific confidentiality frameworks.
Collaborative CDMO Mindset
We align discovery outputs with the questions medicinal chemistry, DMPK, and CMC teams will ask next, making outsourcing more efficient for biotech and pharma clients.
1
Target Review and Program Framing
We review target class, known binders, desired modality profile, route of administration, and screening constraints to define the most relevant cyclic peptide strategy.
2
Sequence and Topology Design
Initial sequence sets are proposed using rational design, literature-derived motifs, structural hypotheses, or screening-informed starting points.
3
Cyclization Route and Analog Planning
We determine the closure chemistry, ring size, and substitution map needed to generate interpretable SAR while keeping synthesis practical.
4
Modeling and Property Assessment
Conformational analysis, docking hypotheses, and developability review are used to prioritize analogs with the best balance of affinity and drug-like behavior.
5
Iterative SAR Optimization
Assay and analytical results are fed back into the design cycle to refine potency, selectivity, stability, solubility, and permeability.
6
Candidate Prioritization and Development Handoff
Final recommendations identify the most promising scaffolds for expanded synthesis, in vivo evaluation, formulation studies, or preclinical development.
Cyclic peptides are particularly valuable where small molecules lack interface coverage and biologics lack tissue access.
We support discovery and optimization programs across therapeutic areas where constrained peptides offer clear scientific or development advantages.
For cyclic peptide programs, candidate quality is determined by a multidimensional balance rather than a single potency metric. The table below highlights the parameters most often used to prioritize lead series for further development.
| Optimization Parameter | What We Measure or Review | Common Design Actions |
|---|---|---|
| Binding Potency | Affinity, functional activity, and target engagement consistency across assay formats | Residue substitution, hotspot reinforcement, topology changes, pharmacophore alignment |
| Selectivity | Counterscreen profile against homologous receptors, enzymes, or off-target panels | Side-chain optimization, ring-size adjustment, conformational bias tuning |
| Serum / Protease Stability | Degradation rate, cleavage hotspots, metabolite pattern | Cyclization refinement, D-amino acids, N-methylation, non-natural residue insertion |
| Permeability | Cell-based uptake or permeability readouts and polarity analysis | Hydrogen-bond shielding, lipophilicity tuning, backbone modification, scaffold compaction |
| Solubility / Formulation Fit | Aqueous behavior, aggregation risk, concentration tolerance | Charge redistribution, salt form, sequence simplification, excipient-compatible design |
| Synthesis and Purification Risk | Cyclization efficiency, impurity burden, route reproducibility | Protecting-group redesign, alternate closure site, simplified analog architecture |
Ready to advance a cyclic peptide program with stronger scientific rationale and clearer development direction?
Our scientists support biotech and pharmaceutical teams with cyclic peptide design, SAR planning, cyclization strategy selection, and developability-focused optimization for discovery and preclinical programs. From early hit generation to candidate-ready lead refinement, we help clients build constrained peptide assets that are better aligned with target biology, assay reality, and downstream manufacturing needs. Contact us now to discuss your target, sequence concept, or screening plan and build a cyclic peptide development strategy tailored to your program.
Cyclic peptides are peptides whose structures are constrained into a ring, improving stability, binding affinity, and resistance to enzymatic degradation. They are widely used in drug discovery to target challenging proteins, including protein–protein interactions.
We support multiple cyclic peptide formats, including head-to-tail cyclization, disulfide-rich peptides, macrocyclic peptides, bicyclic peptides, and stapled peptides, depending on project requirements.
The choice depends on the biological target and project goals. Macrocyclic peptides offer broad structural diversity, bicyclic peptides provide higher binding specificity, and stapled peptides are often used for stabilizing helical structures and intracellular targets.
Cyclic peptide library screening is used to identify novel peptide binders from large peptide libraries. It is typically required in early-stage drug discovery when no lead compounds are available.
Yes, we support cyclic peptide drug discovery programs, including hit identification, lead optimization, and candidate refinement aligned with specific biological targets.
